The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Open accessAbstract
Summary Small molecules that directly target MYC and are also well tolerated in vivo will provide invaluable chemical probes and potential anti-cancer therapeutic agents. We developed a series of small molecule MYC inhibitors that engage MYC inside cells, disrupt MYC/MAX dimers, and impair MYC-driven gene expression. The compounds enhance MYC phosphorylation on threonine-58, consequently increasing proteasome-mediated MYC degradation. The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index. An improved analogue, MYCi975 showed better tolerability. These findings indicate the potential of small molecule MYC inhibitors as chemical probes and possible anti-cancer therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“…N N O O NH O N N N F F F S S S N N O NH O N O HNNHS O O Cl S Cl O O O N H O O (Kiessling et al., 2006) * (Seal et al., 2012) (Yap et al., 2013) *(Filippakopoulos et al., 2010) (Hart et al., 2014) (Mo and Henriksson, 2006) (Jiang et al., 2009) *BET bromodomain inhibitors as decoys F F F N N…”
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Dang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
Large‐scale mapping of human protein–protein interactions by mass spectrometry
Ewing, R. M., Chu, P., Elisma, F., Li, H., Taylor, P., Climie, S., McBroom‐Cerajewski, L., Robinson, M. D., O'Connor, L., Li, M., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100134 · Cited by 984
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Sequence-Specific DNA Binding by the c-Myc Protein
Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N., & Weintraub, H. (1990) · Science · doi:10.1126/science.2251503 · Cited by 872
GSK3: a multifaceted kinase in Wnt signaling
Wu, D., & Pan, W. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.10.002 · Cited by 857
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747
Cdc25 cell-cycle phosphatase as a target of c-myc
Galaktionov, K., Chen, X., & Beach, D. (1996) · Nature · doi:10.1038/382511a0 · Cited by 690
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
MYC, Metabolism, Cell Growth, and Tumorigenesis
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 602
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
Farrell, A. S., & Sears, R. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014365 · Cited by 468
c-Myc regulates mammalian body size by controlling cell number but not cell size
Trumpp, A., Refaeli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G. R., & Bishop, J. M. (2001) · Nature · doi:10.1038/414768a · Cited by 439
Low molecular weight inhibitors of Myc–Max interaction and function
Yin, X., Giap, C., Lazo, J. S., & Prochownik, E. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206641 · Cited by 428
A Quantitative Model of Thermal Stabilization and Destabilization of Proteins by Ligands
Cimmperman, P., Baranauskienė, L., Jachimovičiūtė, S., Jachno, J., Torresan, J., Michailovienė, V., Matulienė, J., Sereikaitė, J., Bumelis, V., & Matulis, D. (2008) · Biophysical Journal · doi:10.1529/biophysj.108.134973 · Cited by 352
Mimura, K., Teh, J. L., Okayama, H., Shiraishi, K., Kua, L., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13424 · Cited by 329
Berg, T., Cohen, S. B., Desharnais, J., Sonderegger, C., Maslyar, D. J., Goldberg, J., Boger, D. L., & Vogt, P. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062036999 · Cited by 326
The significance of the Wnt pathway in the pathology of human cancers
Karim, R. Z., Tse, G. M. K., Putti, T. C., Scolyer, R. A., & Soon Lee, C. (2004) · Pathology · doi:10.1080/00313020410001671957 · Cited by 276
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 259
An evaluation of human protein-protein interaction data in the public domain
Mathivanan, S., Periaswamy, B., Gandhi, T., Kandasamy, K., Suresh, S., Mohmood, R., Ramachandra, Y., & Pandey, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s5-s19 · Cited by 232
Multiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc
Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 229
Therapeutic Strategies to Inhibit MYC
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 222
Dosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Marie-Joseph, E. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 210
Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.041 · Cited by 209
Kalkat, M., Resetca, D., Lourenco, C., Chan, P.-K., Wei, Y., Shiah, Y.-J., Vitkin, N., Tong, Y., Sunnerhagen, M., Done, S. J., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.031 · Cited by 201
Improved low molecular weight Myc-Max inhibitors
Wang, H., Hammoudeh, D. I., Follis, A. V., Reese, B. E., Lazo, J. S., Metallo, S. J., & Prochownik, E. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0005 · Cited by 190
Follis, A. V., Hammoudeh, D. I., Wang, H., Prochownik, E. V., & Metallo, S. J. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.011 · Cited by 183
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 167
Fang, X., Zhou, W., Wu, Q., Huang, Z., Shi, Y., Yang, K., Chen, C., Xie, Q., Mack, S. C., Wang, X., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151673 · Cited by 163
Large-Scale Identification of c-MYC-Associated Proteins Using a Combined TAP/MudPIT Approach
Koch, H., Zhang, R., Verdoodt, B., Bailey, A., Zhang, C.-D., Yates, J. R., Menssen, A., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.2.3742 · Cited by 162
Watson, P. A., Ellwood-Yen, K., King, J. C., Wongvipat, J., LeBeau, M. M., & Sawyers, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3441 · Cited by 159
Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small Molecules
Kiessling, A., Sperl, B., Hollis, A., Eick, D., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.011 · Cited by 153
Inhibitor of MYC identified in a Kröhnke pyridine library
Hart, J. R., Garner, A. L., Yu, J., Ito, Y., Sun, M., Ueno, L. A., Rhee, J., Baksh, M. M., Stefan, E., Hartl, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319488111 · Cited by 150
Guo, J., Parise, R. A., Joseph, E., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0774-y · Cited by 123
Clausen, D. M., Guo, J., Parise, R. A., Beumer, J. H., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170555 · Cited by 117
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 111
MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels
Lu, Y., Hu, Z., Mangala, L. S., Stine, Z. E., Hu, Z., Jiang, D., Xiang, Y., Zhang, Y., Pradeep, S., Rodriguez‐Aguayo, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0815 · Cited by 111
Anker, J. F., Naseem, A. F., Mok, H., Schaeffer, A. J., Abdulkadir, S. A., & Thumbikat, P. (2018) · Nature Communications · doi:10.1038/s41467-018-03900-x · Cited by 110
Self-citationTumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy
Shachaf, C. M., & Felsher, D. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1172 · Cited by 103
Perturbation of the c-Myc–Max Protein–Protein Interaction via Synthetic α-Helix Mimetics
Jung, K., Wang, H., Teriete, P., Yap, J. L., Chen, L., Lanning, M. E., Hu, A., Lambert, L. J., Holien, T., Sundan, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501440q · Cited by 96
A credit-card library approach for disrupting protein–protein interactions
Xu, Y., Shi, J., Yamamoto, N., Moss, J. A., Vogt, P. K., & Janda, K. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.052 · Cited by 93
Discovery of Novel Myc−Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model
Mustata, G. I., Follis, A. V., Hammoudeh, D. I., Metallo, S. J., Wang, H., Prochownik, E. V., Lazo, J. S., & Bahar, İ. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801278g · Cited by 85
Pharmacophore identification of c-Myc inhibitor 10074-G5
Yap, J. L., Wang, H., Hu, A., Chauhan, J., Jung, K.-Y., Gharavi, R. B., Prochownik, E. V., & Fletcher, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.013 · Cited by 83
Mo, H., & Arsenian‐Henriksson, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601418103 · Cited by 81
Proteomic profiling of Myc-associated proteins
Agrawal, P., Yu, K., Salomon, A. R., & Sedivy, J. M. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14199 · Cited by 76
Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function
Jiang, H., Bower, K. E., Beuscher, A. E., Zhou, B., Bobkov, A. A., Olson, A. J., & Vogt, P. K. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.054858 · Cited by 62
Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation
Jin, S. K., Stover, J. S., Whitby, L. R., Vogt, P. K., & Boger, D. L. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.044 · Cited by 59
Dzikiewicz‐Krawczyk, A., Kok, K., Ślęzak-Prochazka, I., Robertus, J. L., Bruining, J., Tayari, M. M., Rutgers, B., de Jong, D., Koerts, J. A., Seitz, A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.94 · Cited by 58
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
Zou, J., Zhuang, M., Yu, X., Li, N., Mao, R., Wang, Z., Wang, J., Wang, X., Zhou, H., Zhang, L., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.07.006 · Cited by 54
Regulation mechanism of Fbxw7-related signaling pathways (Review)
Zhou, Z., He, C., & Wang, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4227 · Cited by 27
Kapeli, K., & Hurlin, P. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276675 · Cited by 19
Unno, K., Roh, M., Yoo, Y. A., Al-Shraideh, Y., Wang, L., Nonn, L., & Abdulkadir, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.17230 · Cited by 19
Self-citation
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Metadata
- Authors
- Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., Mok, H., Vatapalli, R., Yoo, Y. A., Rodriguez, Y., Kandela, I., Parker, J. B., Chakravarti, D., Mishra, R. K., Schiltz, G. E., & Abdulkadir, S. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 36
- Issue
- 5
- Pages
- 483-497.e15
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2982546313
- Cited by
- 465
- References
- 66
- FWCI
- 15.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.